Columnist.
For those who may be unfamiliar with the players in the pharmaceutical business, Mylan is a successful, mid-sized manufacturer of branded and generic drugs. One of their largest products is the EpiPen, which is an auto-injection device used to treat potentially fatal allergic reactions via a quick dose of the drug epinephrine. The company and its CEO are under fire for a recent price increase of the product. In fact, the furor surrounding the price increase of Mylan’s EpiPen has reached critical mass. Since Congress likes nothing more than to jump on the bandwagon of public outrage, the House of Representatives has entered the conversation of “outrageous” prescription drug pricing. The national legislature doesn’t just intend to talk about how Americans are being gouged by big pharmaceutical corporations, however, it intends to do what it does best: legislate the problem away.
